Compass Pathways plc
CMPSDrugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
3
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
3 upcoming, 1 past
How CMPS's past catalysts played out
Psilocybin
Treatment Resistant Depression
CTX-009
Glioblastoma
COMP360 psilocybin
PTSD - Post Traumatic Stress Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Psilocybin | Phase 3 | Treatment Resistant Depression | - | - |
CTX-009 | Phase 3 | Glioblastoma | - | - |
COMP360 psilocybin | Phase 3 | PTSD - Post Traumatic Stress Disorder | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Compass Pathways plc's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Compass Pathways plc's (CMPS) pipeline across Phase 3. Its lead program is Psilocybin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Compass Pathways plc's next FDA catalyst?→
Compass Pathways plc's (CMPS) next tracked catalyst is a Phase 3 expected December 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CMPS biotech catalysts?→
Add CMPS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Compass Pathways plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.